JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
GSK2837808A is a potent, selective lactate dehydrogenase A (LDHA) inhibitor (IC50 values are 1.9 and 14 nM for LDHA and LDHB respectively).
In Snu398 but not HepG2 hepatocellular carcinoma cells. GSK2837808A (10 µM) reduces glucose consumption.
After intravenous injection of GSK2837808A at 0.25 mg/kg in rats, the clearance is shown to be 69 mL/min/kg, which exceeds the blood flow of the animal liver. Oral administration of GSK2837808A at 50 mg/kg or 100 mg/kg in rats or mice, respectively, resulted in blood compound levels reaching or below the detection limit of 2.5 ng/mL.
Reference:
[1]. Billiard J, Dennison J B, Briand J, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer & Metabolism, 2013, 1(1): 19-19.
